First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154
- Monday, April 3, 2023, 7:00
- Finance
- Add a comment
LPCN 1154 is an oral formulation of brexanolone in development for the rapid relief of postpartum depression (PPD) Topline study results expected in H1 2023 SALT LAKE CITY, April 3, 2023 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central…
About the Author
adminasapcorp has written 39689 stories on this site.